Search

Displaying results 7961 - 7970 of 10000 in total
  1. Drug

    INCB-9471

    go.drugbank.com/drugs/DB12960
    Investigational

    INCB-9471 is a novel, orally available CCR5 antagonist that is part of a new class of drugs to treat HIV/AIDS. It is a potent, selective inhibitor of the HIV-1 virus.

  2. Target

    Endoplasmic reticulum membrane sensor NFE2L1

    go.drugbank.com/bio_entities/BE0004168
    TargetHumans

    In response to stress, it is released from the endoplasmic reticulum membrane following cleavage by the protease DDI2 and translocates into the nucleus to form the transcription factor NRF1 (By similarity … Acts as a key sensor of cholesterol excess: in excess cholesterol conditions, the endoplasmic reticulum membrane form of the protein directly binds cholesterol via its CRAC motif, preventing cleavage and

    Synonyms: Protein NRF1, p120 form
  3. Drug

    Docirbrutinib

    go.drugbank.com/drugs/DB21606
    Investigational

    Docirbrutinib is under investigation in clinical trial NCT05602363 (AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma). … Docirbrutinib is a small molecule drug. The usage of the INN stem '-brutinib' in the name indicates that Docirbrutinib is a agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitor.

  4. Drug

    SYNB1891

    go.drugbank.com/drugs/DB17541
    Investigational

    [A256733] SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects). … SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway.

  5. Drug

    AV-COVID-19

    go.drugbank.com/drugs/DB15802
    Investigational

    The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration. … The vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.

  6. Drug

    Furazidin

    go.drugbank.com/drugs/DB13475
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    PF-05241328

    go.drugbank.com/drugs/DB15124
    Investigational

    PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound … Which Will Not Have Any Pharmacological Activity).

  8. Drug

    Vociprotafib

    go.drugbank.com/drugs/DB21559
    Investigational

    Vociprotafib is under investigation in clinical trial NCT05054725 (Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies). … Vociprotafib is a small molecule drug. The usage of the INN stem '-protafib' in the name indicates that Vociprotafib is a human protein tyrosine phosphatase (HPTP) inhibitor.

  9. Drug

    Annamycin

    go.drugbank.com/drugs/DB06420
    Investigational

  10. Drug

    Pamiparib

    go.drugbank.com/drugs/DB14769
    Investigational

    on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy). … Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression